The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
United Therapeutics Corporation (UTHR) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 358.29
(+3.66%)
Based on the United Therapeutics Corporation stock forecast from 9 analysts, the average analyst target price for United Therapeutics Corporation is USD 358.29 over the next 12 months. United Therapeutics Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of United Therapeutics Corporation is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, United Therapeutics Corporation’s stock price was USD 345.63. United Therapeutics Corporation’s stock price has changed by -4.93% over the past week, +7.35% over the past month and +55.25% over the last year.
No recent analyst target price found for United Therapeutics Corporation
No recent average analyst rating found for United Therapeutics Corporation
Company Overview United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Read Less
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI...Read More
Frequently Asked Questions About United Therapeutics Corporation (UTHR) Stock
Based on ratings from 9 analysts United Therapeutics Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, 1 sell and 2 hold ratings.
Unfortunately we do not have enough data on UTHR's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for UTHR is USD 358.29 over the next 12 months. The maximum analyst target price is USD 575 while the minimum anlayst target price is USD 240.
UTHR stock's Price/Earning ratio is 16.23.
Our analysis grades UTHR stock's Price / Earning ratio at F. This means that UTHR stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this UTHR may be a overvalued for its sector.
The last closing price of UTHR's stock was USD 345.63.
The most recent market capitalization for UTHR is USD 15.72B.
Based on targets from 9 analysts, the average taret price for UTHR is projected at USD 358.29 over the next 12 months.
This means that UTHR's stock price may go up by +3.66% over the next 12 months.
We can't find any ETFs which contains United Therapeutics Corporation's stock.
As per our most recent records United Therapeutics Corporation has 1,168 Employees.
United Therapeutics Corporation's registered address is 1000 Spring Street, Silver Spring, MD, United States, 20910.
You can get more information about it from United Therapeutics Corporation's website at https://www.unither.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About United Therapeutics Corporation (UTHR) Stock
Based on ratings from 9 analysts United Therapeutics Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, 1 sell and 2 hold ratings.
Unfortunately we do not have enough data on UTHR's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for UTHR is USD 358.29 over the next 12 months. The maximum analyst target price is USD 575 while the minimum anlayst target price is USD 240.
UTHR stock's Price/Earning ratio is 16.23.
Our analysis grades UTHR stock's Price / Earning ratio at F. This means that UTHR stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this UTHR may be a overvalued for its sector.
The last closing price of UTHR's stock was USD 345.63.
The most recent market capitalization for UTHR is USD 15.72B.
Based on targets from 9 analysts, the average taret price for UTHR is projected at USD 358.29 over the next 12 months.
This means that UTHR's stock price may go up by +3.66% over the next 12 months.
We can't find any ETFs which contains United Therapeutics Corporation's stock.
As per our most recent records United Therapeutics Corporation has 1,168 Employees.
United Therapeutics Corporation's registered address is 1000 Spring Street, Silver Spring, MD, United States, 20910.
You can get more information about it from United Therapeutics Corporation's website at https://www.unither.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for UTHR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
